Educational information only. Not medical advice. Talk to a qualified healthcare professional before using any compound. Disclaimer

LimitlessLab
Search the library Wishlist Cart, items: 0
Retatrutide

Metabolic & Weight

Retatrutide

Also known as LY3437943, Reta

Moderate human evidenceIn clinical trials

Price range: €105 through €165

Discussed for: Very strong weight loss.

Sequence: not listed. Modified or non-standard residues are left out on purpose.

Effect strengthHow hard it acts on the body10/10
Proof levelHow well that is shown in humans7/10
Risk levelHow much can go wrong6/10

Editorial 1 to 10 estimates from published research, not measured values. How to read these

Save to wishlist
Save to wishlist

01 / Identity

What it is

Retatrutide is a synthetic triple agonist. Main reported uses: very strong weight loss. Current status: not approved, in Phase 3 trials (Eli Lilly).

Molecule type
Synthetic triple agonist
How it is taken
Injection (SC weekly)
Other names
LY3437943, Reta

Route only. This library does not publish doses or protocols.

02 / Mechanism

How it is thought to work

Triple agonist (GLP-1, GIP, glucagon); also increases calorie burn

03 / Potential benefits

What people use it for

Very strong weight loss

Moderate human evidence

Some human trials exist, but they are smaller, shorter or mixed.

Listed uses are what people use it for, not proven outcomes.

04 / Known risks

Side effects and risks

Nausea, raised heart rate, GI issues; grey-market vials unregulated

Risk level 6 of 10

Moderate risk score: real side effects are known, and long-term safety is not settled.

Unknown long-term effects count as a risk, not as a clean record.

05 / Regulatory

Regulatory status

Status
In clinical trials
Details
Not approved, in Phase 3 trials (Eli Lilly)
Sport (WADA)
Not listed (S0 risk while unapproved)

Status reflects information up to mid-2026 and changes over time. Check current sources.

06 / Evidence quality

How good is the evidence?

Moderate to strong: trial data

How we grade evidence

07 / Notes and sources

Notes and sources

  • Products sold online as research peptides are unregulated. Tests of such products often find wrong amounts, impurities or a different compound.
  • Anyone using compounds like this regularly should have medical supervision and bloodwork (for example IGF-1, glucose and HbA1c, hormones, lipids).
  • Source: Peptide Reference Table, an editorial review of published research up to mid-2026. Scores are 1 to 10 editorial estimates, not measured values. Regulatory and WADA status change over time.

Educational information only. Not medical advice. Talk to a qualified healthcare professional before using any compound.

Related compounds